Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.
Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.
复制标题
DOI：
10.1186/1743-422x-7-299
复制
发表时间：
2010-11-04
期刊：
影响因子：
4.8
通讯作者：
He Y
中科院分区：
文献类型：
--
作者：
Cao Z;Liu L;Du L;Zhang C;Jiang S;Li T;He Y
SARS冠状病毒的S蛋白(S)不仅能介导受体结合，还能诱导中和抗体。我们先前将S蛋白的受体结合区确定为动物模型中和抗体的主要靶点，并据此提出了一种基于受体结合域的疫苗。然而，RBD在人类中的抗原性和免疫原性还需要表征。用双抗体夹心法和微量中和试验检测SARS康复期患者血清中的RBD抗体。我们发现S蛋白的RBD在康复的SARS患者中诱导了强大的抗体应答，并且RBD特异性抗体可以在三年以上的随访中保持高滴度。此外，亲和纯化的抗RBD抗体具有较强的中和活性。SARS-CoV的RBD对人类具有高度的免疫原性，并介导保护性反应，基于RBD的疫苗和诊断方法可以进一步开发。
The spike (S) protein of SARS-CoV not only mediates receptor-binding but also induces neutralizing antibodies. We previously identified the receptor-binding domain (RBD) of S protein as a major target of neutralizing antibodies in animal models and thus proposed a RBD-based vaccine. However, the antigenicity and immunogenicity of RBD in humans need to be characterized. Two panels of serum samples from recovered SARS patients were included and the antibody responses against the RBD were measured by ELISA and micro-neutralization assays. We found that the RBD of S protein induced potent antibody responses in the recovered SARS patients and RBD-specific antibodies could persist at high titers over three year follow-up. Furthermore, affinity purified anti-RBD antibodies possessed robust neutralizing activity. The RBD of SARS-CoV is highly immunogenic in humans and mediates protective responses and RBD-based vaccines and diagnostic approaches can be further developed.